UA71555C2 - Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives - Google Patents
Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives Download PDFInfo
- Publication number
- UA71555C2 UA71555C2 UA2000052578A UA2000052578A UA71555C2 UA 71555 C2 UA71555 C2 UA 71555C2 UA 2000052578 A UA2000052578 A UA 2000052578A UA 2000052578 A UA2000052578 A UA 2000052578A UA 71555 C2 UA71555 C2 UA 71555C2
- Authority
- UA
- Ukraine
- Prior art keywords
- group
- alkyl
- aforementioned
- independently selected
- residues
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 158
- 102100030011 Endoribonuclease Human genes 0.000 title claims abstract description 37
- 101710199605 Endoribonuclease Proteins 0.000 title claims abstract description 37
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 title claims abstract description 37
- VMLKTERJLVWEJJ-UHFFFAOYSA-N 1,5-naphthyridine Chemical class C1=CC=NC2=CC=CN=C21 VMLKTERJLVWEJJ-UHFFFAOYSA-N 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 283
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 52
- 201000010099 disease Diseases 0.000 claims abstract description 38
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 108060006633 protein kinase Proteins 0.000 claims description 119
- 102000001253 Protein Kinase Human genes 0.000 claims description 118
- 125000000217 alkyl group Chemical group 0.000 claims description 59
- 125000003118 aryl group Chemical group 0.000 claims description 59
- 125000001424 substituent group Chemical group 0.000 claims description 49
- -1 benzylamino benzylamino 4-hydroxyphenyl Chemical group 0.000 claims description 41
- 229910052736 halogen Inorganic materials 0.000 claims description 41
- 150000002367 halogens Chemical group 0.000 claims description 41
- YEYHFKBVNARCNE-UHFFFAOYSA-N pyrido[2,3-b]pyrazine Chemical group N1=CC=NC2=CC=CN=C21 YEYHFKBVNARCNE-UHFFFAOYSA-N 0.000 claims description 41
- 239000001257 hydrogen Substances 0.000 claims description 37
- 229910052739 hydrogen Inorganic materials 0.000 claims description 37
- 230000000694 effects Effects 0.000 claims description 36
- 150000002148 esters Chemical group 0.000 claims description 35
- 125000004953 trihalomethyl group Chemical group 0.000 claims description 34
- 206010028980 Neoplasm Diseases 0.000 claims description 33
- 125000001072 heteroaryl group Chemical group 0.000 claims description 32
- 229920006395 saturated elastomer Polymers 0.000 claims description 32
- 125000004417 unsaturated alkyl group Chemical group 0.000 claims description 32
- 239000000758 substrate Substances 0.000 claims description 31
- 150000007942 carboxylates Chemical group 0.000 claims description 28
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 28
- 230000008859 change Effects 0.000 claims description 27
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 22
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 22
- 201000011510 cancer Diseases 0.000 claims description 22
- 150000002431 hydrogen Chemical class 0.000 claims description 22
- 125000003545 alkoxy group Chemical group 0.000 claims description 21
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 20
- 239000007787 solid Substances 0.000 claims description 19
- 230000003993 interaction Effects 0.000 claims description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 17
- 230000004663 cell proliferation Effects 0.000 claims description 17
- 102100028921 Serine/threonine-protein kinase MARK1 Human genes 0.000 claims description 15
- 239000003153 chemical reaction reagent Substances 0.000 claims description 15
- 230000003197 catalytic effect Effects 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- MTMONFVFAYLRSG-UHFFFAOYSA-N 2-(4-hydroxyphenyl)-2-oxoacetaldehyde Chemical compound OC1=CC=C(C(=O)C=O)C=C1 MTMONFVFAYLRSG-UHFFFAOYSA-N 0.000 claims description 11
- 239000006166 lysate Substances 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 239000001301 oxygen Substances 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 238000001179 sorption measurement Methods 0.000 claims description 9
- BVQVLAIMHVDZEL-UHFFFAOYSA-N 1-phenyl-1,2-propanedione Chemical compound CC(=O)C(=O)C1=CC=CC=C1 BVQVLAIMHVDZEL-UHFFFAOYSA-N 0.000 claims description 8
- 206010016654 Fibrosis Diseases 0.000 claims description 7
- 229910019142 PO4 Inorganic materials 0.000 claims description 7
- 150000001412 amines Chemical group 0.000 claims description 7
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 7
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 7
- 239000003054 catalyst Substances 0.000 claims description 7
- 238000011534 incubation Methods 0.000 claims description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 7
- 239000010452 phosphate Substances 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 150000001408 amides Chemical class 0.000 claims description 6
- 230000004761 fibrosis Effects 0.000 claims description 6
- 230000002194 synthesizing effect Effects 0.000 claims description 6
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 150000001299 aldehydes Chemical class 0.000 claims description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 5
- 150000002576 ketones Chemical class 0.000 claims description 5
- 229910052700 potassium Inorganic materials 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 239000003638 chemical reducing agent Substances 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 230000037361 pathway Effects 0.000 claims description 4
- 150000003457 sulfones Chemical class 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000032612 Glial tumor Diseases 0.000 claims description 3
- 206010018338 Glioma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- WURBFLDFSFBTLW-UHFFFAOYSA-N benzil Chemical group C=1C=CC=CC=1C(=O)C(=O)C1=CC=CC=C1 WURBFLDFSFBTLW-UHFFFAOYSA-N 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 230000009089 cytolysis Effects 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- WERABQRUGJIMKQ-UHFFFAOYSA-N 6-chloro-3-nitropyridin-2-amine Chemical group NC1=NC(Cl)=CC=C1[N+]([O-])=O WERABQRUGJIMKQ-UHFFFAOYSA-N 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 229910000564 Raney nickel Inorganic materials 0.000 claims description 2
- 125000003158 alcohol group Chemical group 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 238000012544 monitoring process Methods 0.000 claims 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical group [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 claims 1
- 230000005540 biological transmission Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- LJDZFAPLPVPTBD-UHFFFAOYSA-N nitroformic acid Chemical group OC(=O)[N+]([O-])=O LJDZFAPLPVPTBD-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 125000001174 sulfone group Chemical group 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 13
- 230000004060 metabolic process Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 147
- 230000006870 function Effects 0.000 description 48
- 108090000623 proteins and genes Proteins 0.000 description 32
- 238000012360 testing method Methods 0.000 description 29
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 24
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 23
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 23
- 230000026731 phosphorylation Effects 0.000 description 23
- 238000006366 phosphorylation reaction Methods 0.000 description 23
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 102000005962 receptors Human genes 0.000 description 17
- 108020003175 receptors Proteins 0.000 description 17
- 239000000243 solution Substances 0.000 description 14
- 108091054455 MAP kinase family Proteins 0.000 description 13
- 102000043136 MAP kinase family Human genes 0.000 description 13
- 230000002159 abnormal effect Effects 0.000 description 13
- 208000035475 disorder Diseases 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 101001059443 Homo sapiens Serine/threonine-protein kinase MARK1 Proteins 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 239000000872 buffer Substances 0.000 description 12
- 230000035755 proliferation Effects 0.000 description 12
- 108091000080 Phosphotransferase Proteins 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 102000020233 phosphotransferase Human genes 0.000 description 11
- 230000012010 growth Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical group [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical group CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- OJUGVDODNPJEEC-UHFFFAOYSA-N phenylglyoxal Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 239000000376 reactant Substances 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 230000008054 signal transmission Effects 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- IIFVWLUQBAIPMJ-UHFFFAOYSA-N (4-fluorophenyl)methanamine Chemical compound NCC1=CC=C(F)C=C1 IIFVWLUQBAIPMJ-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
- 239000004473 Threonine Substances 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 230000006037 cell lysis Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000011067 equilibration Methods 0.000 description 4
- 239000003517 fume Substances 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000001488 sodium phosphate Substances 0.000 description 4
- 229910000162 sodium phosphate Inorganic materials 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- ZKKBWNOSVZIFNJ-UHFFFAOYSA-N 2-amino-3,7-dihydropurin-6-one;diphosphono hydrogen phosphate Chemical compound O=C1NC(N)=NC2=C1NC=N2.OP(O)(=O)OP(O)(=O)OP(O)(O)=O ZKKBWNOSVZIFNJ-UHFFFAOYSA-N 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 108091008606 PDGF receptors Proteins 0.000 description 3
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 3
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 3
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 101000944274 Rattus norvegicus ATP-sensitive inward rectifier potassium channel 1 Proteins 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 229910052759 nickel Inorganic materials 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 229940080469 phosphocellulose Drugs 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 230000004862 vasculogenesis Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 2
- 102100039445 Cortexin-3 Human genes 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 description 2
- 108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101100061721 Homo sapiens CTXN3 gene Proteins 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 150000001345 alkine derivatives Chemical class 0.000 description 2
- 150000001448 anilines Chemical class 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 150000003939 benzylamines Chemical class 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 208000035269 cancer or benign tumor Diseases 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 230000004118 muscle contraction Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- MWWXGLIRWHESLA-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-2,3-diphenylpyrido[2,3-b]pyrazin-6-amine Chemical compound C1=CC(F)=CC=C1CNC1=CC=C(N=C(C=2C=CC=CC=2)C(=N2)C=3C=CC=CC=3)C2=N1 MWWXGLIRWHESLA-UHFFFAOYSA-N 0.000 description 2
- LZBURQBYLWSOAN-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-2-methyl-3-phenylpyrido[2,3-b]pyrazin-6-amine Chemical compound N1=C2N=C(C=3C=CC=CC=3)C(C)=NC2=CC=C1NCC1=CC=C(F)C=C1 LZBURQBYLWSOAN-UHFFFAOYSA-N 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229920002704 polyhistidine Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 230000022983 regulation of cell cycle Effects 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- KDDNKZCVYQDGKE-UHFFFAOYSA-N (2-chlorophenyl)methanamine Chemical compound NCC1=CC=CC=C1Cl KDDNKZCVYQDGKE-UHFFFAOYSA-N 0.000 description 1
- LRFWYBZWRQWZIM-UHFFFAOYSA-N (2-fluorophenyl)methanamine Chemical compound NCC1=CC=CC=C1F LRFWYBZWRQWZIM-UHFFFAOYSA-N 0.000 description 1
- CJAAPVQEZPAQNI-UHFFFAOYSA-N (2-methylphenyl)methanamine Chemical compound CC1=CC=CC=C1CN CJAAPVQEZPAQNI-UHFFFAOYSA-N 0.000 description 1
- PYYRNLDFMZVKCV-UHFFFAOYSA-N (2-nitrophenyl)methanamine Chemical compound NCC1=CC=CC=C1[N+]([O-])=O PYYRNLDFMZVKCV-UHFFFAOYSA-N 0.000 description 1
- BJFPYGGTDAYECS-UHFFFAOYSA-N (3-chlorophenyl)methanamine Chemical compound NCC1=CC=CC(Cl)=C1 BJFPYGGTDAYECS-UHFFFAOYSA-N 0.000 description 1
- QVSVMNXRLWSNGS-UHFFFAOYSA-N (3-fluorophenyl)methanamine Chemical compound NCC1=CC=CC(F)=C1 QVSVMNXRLWSNGS-UHFFFAOYSA-N 0.000 description 1
- CIUYJYRQKYGNQP-UHFFFAOYSA-N (3-nitrophenyl)methanamine Chemical compound NCC1=CC=CC([N+]([O-])=O)=C1 CIUYJYRQKYGNQP-UHFFFAOYSA-N 0.000 description 1
- YMVFJGSXZNNUDW-UHFFFAOYSA-N (4-chlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C=C1 YMVFJGSXZNNUDW-UHFFFAOYSA-N 0.000 description 1
- HMTSWYPNXFHGEP-UHFFFAOYSA-N (4-methylphenyl)methanamine Chemical compound CC1=CC=C(CN)C=C1 HMTSWYPNXFHGEP-UHFFFAOYSA-N 0.000 description 1
- KOFLVDBWRHFSAB-UHFFFAOYSA-N 1,2,4,5-tetrahydro-1-(phenylmethyl)-5,9b(1',2')-benzeno-9bh-benz(g)indol-3(3ah)-one Chemical compound C1C(C=2C3=CC=CC=2)C2=CC=CC=C2C23C1C(=O)CN2CC1=CC=CC=C1 KOFLVDBWRHFSAB-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- RCMLKQSZCSYLLS-UHFFFAOYSA-N 1-hydroxy-2,3-dihydroindole Chemical compound C1=CC=C2N(O)CCC2=C1 RCMLKQSZCSYLLS-UHFFFAOYSA-N 0.000 description 1
- CLTMYNWFSDZKKI-UHFFFAOYSA-N 2-(aminomethyl)benzoic acid Chemical compound NCC1=CC=CC=C1C(O)=O CLTMYNWFSDZKKI-UHFFFAOYSA-N 0.000 description 1
- VBLXCTYLWZJBKA-UHFFFAOYSA-N 2-(trifluoromethyl)aniline Chemical compound NC1=CC=CC=C1C(F)(F)F VBLXCTYLWZJBKA-UHFFFAOYSA-N 0.000 description 1
- MHESVQZGSVCZAC-UHFFFAOYSA-N 2-[(3-phenylpyrido[2,3-b]pyrazin-6-yl)amino]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=C(N=CC(=N2)C=3C=CC=CC=3)C2=N1 MHESVQZGSVCZAC-UHFFFAOYSA-N 0.000 description 1
- RUCLXLRNTUZHNZ-UHFFFAOYSA-N 2-[[(3-phenylpyrido[2,3-b]pyrazin-6-yl)amino]methyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1CNC1=CC=C(N=CC(=N2)C=3C=CC=CC=3)C2=N1 RUCLXLRNTUZHNZ-UHFFFAOYSA-N 0.000 description 1
- QQDYOMXJFPMERF-UHFFFAOYSA-N 2-[[3-(4-hydroxyphenyl)pyrido[2,3-b]pyrazin-6-yl]amino]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=C(N=CC(=N2)C=3C=CC(O)=CC=3)C2=N1 QQDYOMXJFPMERF-UHFFFAOYSA-N 0.000 description 1
- KQYXZGLYCKQYTP-UHFFFAOYSA-N 2-[[[3-(4-hydroxyphenyl)pyrido[2,3-b]pyrazin-6-yl]amino]methyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1CNC1=CC=C(N=CC(=N2)C=3C=CC(O)=CC=3)C2=N1 KQYXZGLYCKQYTP-UHFFFAOYSA-N 0.000 description 1
- JWDLEVZYUTZUBA-UHFFFAOYSA-N 2-amino-3,7-dihydropurin-6-one;phosphono dihydrogen phosphate Chemical compound OP(O)(=O)OP(O)(O)=O.O=C1NC(N)=NC2=C1NC=N2 JWDLEVZYUTZUBA-UHFFFAOYSA-N 0.000 description 1
- AKCRQHGQIJBRMN-UHFFFAOYSA-N 2-chloroaniline Chemical compound NC1=CC=CC=C1Cl AKCRQHGQIJBRMN-UHFFFAOYSA-N 0.000 description 1
- FTZQXOJYPFINKJ-UHFFFAOYSA-N 2-fluoroaniline Chemical compound NC1=CC=CC=C1F FTZQXOJYPFINKJ-UHFFFAOYSA-N 0.000 description 1
- DPJCXCZTLWNFOH-UHFFFAOYSA-N 2-nitroaniline Chemical compound NC1=CC=CC=C1[N+]([O-])=O DPJCXCZTLWNFOH-UHFFFAOYSA-N 0.000 description 1
- RYCSNJCJOVQGBC-UHFFFAOYSA-N 3-(1-cyclopropyl-2h-pyridin-4-yl)-1h-quinolin-2-one Chemical class O=C1NC2=CC=CC=C2C=C1C(C=C1)=CCN1C1CC1 RYCSNJCJOVQGBC-UHFFFAOYSA-N 0.000 description 1
- GSWYUZQBLVUEPH-UHFFFAOYSA-N 3-(azaniumylmethyl)benzoate Chemical compound NCC1=CC=CC(C(O)=O)=C1 GSWYUZQBLVUEPH-UHFFFAOYSA-N 0.000 description 1
- VIUDTWATMPPKEL-UHFFFAOYSA-N 3-(trifluoromethyl)aniline Chemical compound NC1=CC=CC(C(F)(F)F)=C1 VIUDTWATMPPKEL-UHFFFAOYSA-N 0.000 description 1
- GVVBYDKYLVYSAV-UHFFFAOYSA-N 3-[(3-phenylpyrido[2,3-b]pyrazin-6-yl)amino]benzoic acid Chemical compound OC(=O)C1=CC=CC(NC=2N=C3N=C(C=NC3=CC=2)C=2C=CC=CC=2)=C1 GVVBYDKYLVYSAV-UHFFFAOYSA-N 0.000 description 1
- RZDCSXRATUXMFI-UHFFFAOYSA-N 3-[[(3-phenylpyrido[2,3-b]pyrazin-6-yl)amino]methyl]benzoic acid Chemical compound OC(=O)C1=CC=CC(CNC=2N=C3N=C(C=NC3=CC=2)C=2C=CC=CC=2)=C1 RZDCSXRATUXMFI-UHFFFAOYSA-N 0.000 description 1
- NQOSAGUGNXRVMA-UHFFFAOYSA-N 3-[[3-(4-hydroxyphenyl)pyrido[2,3-b]pyrazin-6-yl]amino]benzoic acid Chemical compound OC(=O)C1=CC=CC(NC=2N=C3N=C(C=NC3=CC=2)C=2C=CC(O)=CC=2)=C1 NQOSAGUGNXRVMA-UHFFFAOYSA-N 0.000 description 1
- GZVGNFWXIXAUQW-UHFFFAOYSA-N 3-[[[3-(4-hydroxyphenyl)pyrido[2,3-b]pyrazin-6-yl]amino]methyl]benzoic acid Chemical compound OC(=O)C1=CC=CC(CNC=2N=C3N=C(C=NC3=CC=2)C=2C=CC(O)=CC=2)=C1 GZVGNFWXIXAUQW-UHFFFAOYSA-N 0.000 description 1
- XFDUHJPVQKIXHO-UHFFFAOYSA-N 3-aminobenzoic acid Chemical compound NC1=CC=CC(C(O)=O)=C1 XFDUHJPVQKIXHO-UHFFFAOYSA-N 0.000 description 1
- PNPCRKVUWYDDST-UHFFFAOYSA-N 3-chloroaniline Chemical compound NC1=CC=CC(Cl)=C1 PNPCRKVUWYDDST-UHFFFAOYSA-N 0.000 description 1
- QZVQQUVWFIZUBQ-UHFFFAOYSA-N 3-fluoroaniline Chemical compound NC1=CC=CC(F)=C1 QZVQQUVWFIZUBQ-UHFFFAOYSA-N 0.000 description 1
- JJYPMNFTHPTTDI-UHFFFAOYSA-N 3-methylaniline Chemical compound CC1=CC=CC(N)=C1 JJYPMNFTHPTTDI-UHFFFAOYSA-N 0.000 description 1
- XJCVRTZCHMZPBD-UHFFFAOYSA-N 3-nitroaniline Chemical compound NC1=CC=CC([N+]([O-])=O)=C1 XJCVRTZCHMZPBD-UHFFFAOYSA-N 0.000 description 1
- HYFGDDIFPKSYDV-UHFFFAOYSA-N 4-(6-anilinopyrido[2,3-b]pyrazin-3-yl)phenol Chemical compound C1=CC(O)=CC=C1C1=CN=C(C=CC(NC=2C=CC=CC=2)=N2)C2=N1 HYFGDDIFPKSYDV-UHFFFAOYSA-N 0.000 description 1
- CPLWOTYKNIVBEG-UHFFFAOYSA-N 4-[(3-phenylpyrido[2,3-b]pyrazin-6-yl)amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=CC=C(N=CC(=N2)C=3C=CC=CC=3)C2=N1 CPLWOTYKNIVBEG-UHFFFAOYSA-N 0.000 description 1
- QYPVPSQBDCAXDV-UHFFFAOYSA-N 4-[6-(2-chloroanilino)pyrido[2,3-b]pyrazin-3-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=CN=C(C=CC(NC=2C(=CC=CC=2)Cl)=N2)C2=N1 QYPVPSQBDCAXDV-UHFFFAOYSA-N 0.000 description 1
- ZMUQPYLMALJIEK-UHFFFAOYSA-N 4-[6-(2-fluoroanilino)pyrido[2,3-b]pyrazin-3-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=CN=C(C=CC(NC=2C(=CC=CC=2)F)=N2)C2=N1 ZMUQPYLMALJIEK-UHFFFAOYSA-N 0.000 description 1
- FTKSGYHJUFTQIS-UHFFFAOYSA-N 4-[6-(2-nitroanilino)pyrido[2,3-b]pyrazin-3-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=CN=C(C=CC(NC=2C(=CC=CC=2)[N+]([O-])=O)=N2)C2=N1 FTKSGYHJUFTQIS-UHFFFAOYSA-N 0.000 description 1
- DQTGVLHYAZDMGZ-UHFFFAOYSA-N 4-[6-(3-chloroanilino)pyrido[2,3-b]pyrazin-3-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=CN=C(C=CC(NC=2C=C(Cl)C=CC=2)=N2)C2=N1 DQTGVLHYAZDMGZ-UHFFFAOYSA-N 0.000 description 1
- GYOZCWRXXQXKPG-UHFFFAOYSA-N 4-[6-(3-fluoroanilino)pyrido[2,3-b]pyrazin-3-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=CN=C(C=CC(NC=2C=C(F)C=CC=2)=N2)C2=N1 GYOZCWRXXQXKPG-UHFFFAOYSA-N 0.000 description 1
- XGINYCUAPVYGPA-UHFFFAOYSA-N 4-[6-(3-methylanilino)pyrido[2,3-b]pyrazin-3-yl]phenol Chemical compound CC1=CC=CC(NC=2N=C3N=C(C=NC3=CC=2)C=2C=CC(O)=CC=2)=C1 XGINYCUAPVYGPA-UHFFFAOYSA-N 0.000 description 1
- MNLIUBKUFGFXIH-UHFFFAOYSA-N 4-[6-(3-nitroanilino)pyrido[2,3-b]pyrazin-3-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=CN=C(C=CC(NC=2C=C(C=CC=2)[N+]([O-])=O)=N2)C2=N1 MNLIUBKUFGFXIH-UHFFFAOYSA-N 0.000 description 1
- CYNHNCDWMAWMSG-UHFFFAOYSA-N 4-[6-(4-chloroanilino)pyrido[2,3-b]pyrazin-3-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=CN=C(C=CC(NC=2C=CC(Cl)=CC=2)=N2)C2=N1 CYNHNCDWMAWMSG-UHFFFAOYSA-N 0.000 description 1
- DFDWWINUNAWXOL-UHFFFAOYSA-N 4-[6-(4-fluoroanilino)pyrido[2,3-b]pyrazin-3-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=CN=C(C=CC(NC=2C=CC(F)=CC=2)=N2)C2=N1 DFDWWINUNAWXOL-UHFFFAOYSA-N 0.000 description 1
- PFUYJSOGTDIVCI-UHFFFAOYSA-N 4-[6-(4-methylanilino)pyrido[2,3-b]pyrazin-3-yl]phenol Chemical compound C1=CC(C)=CC=C1NC1=CC=C(N=CC(=N2)C=3C=CC(O)=CC=3)C2=N1 PFUYJSOGTDIVCI-UHFFFAOYSA-N 0.000 description 1
- UXUHARQBHWJNAS-UHFFFAOYSA-N 4-[6-(4-nitroanilino)pyrido[2,3-b]pyrazin-3-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=CN=C(C=CC(NC=2C=CC(=CC=2)[N+]([O-])=O)=N2)C2=N1 UXUHARQBHWJNAS-UHFFFAOYSA-N 0.000 description 1
- SZJZMVSEUZYAJO-UHFFFAOYSA-N 4-[6-[(2-chlorophenyl)methylamino]pyrido[2,3-b]pyrazin-3-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=CN=C(C=CC(NCC=2C(=CC=CC=2)Cl)=N2)C2=N1 SZJZMVSEUZYAJO-UHFFFAOYSA-N 0.000 description 1
- ZRYJWDUYBWGMAV-UHFFFAOYSA-N 4-[6-[(2-fluorophenyl)methylamino]pyrido[2,3-b]pyrazin-3-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=CN=C(C=CC(NCC=2C(=CC=CC=2)F)=N2)C2=N1 ZRYJWDUYBWGMAV-UHFFFAOYSA-N 0.000 description 1
- BXKZIIKORKUGIS-UHFFFAOYSA-N 4-[6-[(2-methylphenyl)methylamino]pyrido[2,3-b]pyrazin-3-yl]phenol Chemical compound CC1=CC=CC=C1CNC1=CC=C(N=CC(=N2)C=3C=CC(O)=CC=3)C2=N1 BXKZIIKORKUGIS-UHFFFAOYSA-N 0.000 description 1
- XBLCFOBWMYWRGB-UHFFFAOYSA-N 4-[6-[(2-nitrophenyl)methylamino]pyrido[2,3-b]pyrazin-3-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=CN=C(C=CC(NCC=2C(=CC=CC=2)[N+]([O-])=O)=N2)C2=N1 XBLCFOBWMYWRGB-UHFFFAOYSA-N 0.000 description 1
- MPKJTGWGEWVWNL-UHFFFAOYSA-N 4-[6-[(3-chlorophenyl)methylamino]pyrido[2,3-b]pyrazin-3-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=CN=C(C=CC(NCC=2C=C(Cl)C=CC=2)=N2)C2=N1 MPKJTGWGEWVWNL-UHFFFAOYSA-N 0.000 description 1
- INYVOZRUKRVMOX-UHFFFAOYSA-N 4-[6-[(3-fluorophenyl)methylamino]pyrido[2,3-b]pyrazin-3-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=CN=C(C=CC(NCC=2C=C(F)C=CC=2)=N2)C2=N1 INYVOZRUKRVMOX-UHFFFAOYSA-N 0.000 description 1
- RVWZFJZUYKWLMU-UHFFFAOYSA-N 4-[6-[(3-methylphenyl)methylamino]pyrido[2,3-b]pyrazin-3-yl]phenol Chemical compound CC1=CC=CC(CNC=2N=C3N=C(C=NC3=CC=2)C=2C=CC(O)=CC=2)=C1 RVWZFJZUYKWLMU-UHFFFAOYSA-N 0.000 description 1
- ZWXBKBXBFDTPRB-UHFFFAOYSA-N 4-[6-[(3-nitrophenyl)methylamino]pyrido[2,3-b]pyrazin-3-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=CN=C(C=CC(NCC=2C=C(C=CC=2)[N+]([O-])=O)=N2)C2=N1 ZWXBKBXBFDTPRB-UHFFFAOYSA-N 0.000 description 1
- JDBNBLZEKOGBAP-UHFFFAOYSA-N 4-[6-[(4-chlorophenyl)methylamino]pyrido[2,3-b]pyrazin-3-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=CN=C(C=CC(NCC=2C=CC(Cl)=CC=2)=N2)C2=N1 JDBNBLZEKOGBAP-UHFFFAOYSA-N 0.000 description 1
- KMIPNIKFUQZYAQ-UHFFFAOYSA-N 4-[6-[(4-fluorophenyl)methylamino]pyrido[2,3-b]pyrazin-3-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=CN=C(C=CC(NCC=2C=CC(F)=CC=2)=N2)C2=N1 KMIPNIKFUQZYAQ-UHFFFAOYSA-N 0.000 description 1
- VWAKUFHXNSXASX-UHFFFAOYSA-N 4-[6-[(4-methylphenyl)methylamino]pyrido[2,3-b]pyrazin-3-yl]phenol Chemical compound C1=CC(C)=CC=C1CNC1=CC=C(N=CC(=N2)C=3C=CC(O)=CC=3)C2=N1 VWAKUFHXNSXASX-UHFFFAOYSA-N 0.000 description 1
- GKFWRODLDBTAMZ-UHFFFAOYSA-N 4-[6-[(4-nitrophenyl)methylamino]pyrido[2,3-b]pyrazin-3-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=CN=C(C=CC(NCC=2C=CC(=CC=2)[N+]([O-])=O)=N2)C2=N1 GKFWRODLDBTAMZ-UHFFFAOYSA-N 0.000 description 1
- FHAHLLMSPCAPLW-UHFFFAOYSA-N 4-[[(3-phenylpyrido[2,3-b]pyrazin-6-yl)amino]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CNC1=CC=C(N=CC(=N2)C=3C=CC=CC=3)C2=N1 FHAHLLMSPCAPLW-UHFFFAOYSA-N 0.000 description 1
- PBPRXIFWXCIMQH-UHFFFAOYSA-N 4-[[3-(4-hydroxyphenyl)pyrido[2,3-b]pyrazin-6-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=CC=C(N=CC(=N2)C=3C=CC(O)=CC=3)C2=N1 PBPRXIFWXCIMQH-UHFFFAOYSA-N 0.000 description 1
- OXAOTTHDEBCSOL-UHFFFAOYSA-N 4-[[[3-(4-hydroxyphenyl)pyrido[2,3-b]pyrazin-6-yl]amino]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CNC1=CC=C(N=CC(=N2)C=3C=CC(O)=CC=3)C2=N1 OXAOTTHDEBCSOL-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical class C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 1
- KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
- 229940073735 4-hydroxy acetophenone Drugs 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 1
- OZRGLPAXIYOWIG-HZPUXBNGSA-N 4-nitrobenzylamine Chemical compound CC(C)C(CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CCC4=CCCC[C@]4(C)[C@H]3CC[C@]12C)=O OZRGLPAXIYOWIG-HZPUXBNGSA-N 0.000 description 1
- ODGIMMLDVSWADK-UHFFFAOYSA-N 4-trifluoromethylaniline Chemical compound NC1=CC=C(C(F)(F)F)C=C1 ODGIMMLDVSWADK-UHFFFAOYSA-N 0.000 description 1
- RAGAMBSCSBOXBU-UHFFFAOYSA-N 6-n-benzyl-3-nitropyridine-2,6-diamine Chemical compound C1=C([N+]([O-])=O)C(N)=NC(NCC=2C=CC=CC=2)=C1 RAGAMBSCSBOXBU-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OGBVRMYSNSKIEF-UHFFFAOYSA-N Benzylphosphonic acid Chemical compound OP(O)(=O)CC1=CC=CC=C1 OGBVRMYSNSKIEF-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010063209 Chronic allograft nephropathy Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100036725 Epithelial discoidin domain-containing receptor 1 Human genes 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 1
- 108060006687 MAP kinase kinase kinase Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- ZSKQIFWUTUZAGF-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]methanamine Chemical compound NCC1=CC=CC=C1C(F)(F)F ZSKQIFWUTUZAGF-UHFFFAOYSA-N 0.000 description 1
- YKNZTUQUXUXTLE-UHFFFAOYSA-N [3-(trifluoromethyl)phenyl]methanamine Chemical compound NCC1=CC=CC(C(F)(F)F)=C1 YKNZTUQUXUXTLE-UHFFFAOYSA-N 0.000 description 1
- PRDBLLIPPDOICK-UHFFFAOYSA-N [4-(trifluoromethyl)phenyl]methanamine Chemical compound NCC1=CC=C(C(F)(F)F)C=C1 PRDBLLIPPDOICK-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- QCTBMLYLENLHLA-UHFFFAOYSA-N aminomethylbenzoic acid Chemical compound NCC1=CC=C(C(O)=O)C=C1 QCTBMLYLENLHLA-UHFFFAOYSA-N 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229960004979 fampridine Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- AYDZCGMPDRWTMO-UHFFFAOYSA-N n-(2-chlorophenyl)-3-phenylpyrido[2,3-b]pyrazin-6-amine Chemical compound ClC1=CC=CC=C1NC1=CC=C(N=CC(=N2)C=3C=CC=CC=3)C2=N1 AYDZCGMPDRWTMO-UHFFFAOYSA-N 0.000 description 1
- WFDBAJCHFFCAJZ-UHFFFAOYSA-N n-(2-methylphenyl)-3-phenylpyrido[2,3-b]pyrazin-6-amine Chemical compound CC1=CC=CC=C1NC1=CC=C(N=CC(=N2)C=3C=CC=CC=3)C2=N1 WFDBAJCHFFCAJZ-UHFFFAOYSA-N 0.000 description 1
- YRTMRQFHXWWYRY-UHFFFAOYSA-N n-(2-nitrophenyl)-3-phenylpyrido[2,3-b]pyrazin-6-amine Chemical compound [O-][N+](=O)C1=CC=CC=C1NC1=CC=C(N=CC(=N2)C=3C=CC=CC=3)C2=N1 YRTMRQFHXWWYRY-UHFFFAOYSA-N 0.000 description 1
- IWEKKSIVEGWURB-UHFFFAOYSA-N n-(3-methylphenyl)-3-phenylpyrido[2,3-b]pyrazin-6-amine Chemical compound CC1=CC=CC(NC=2N=C3N=C(C=NC3=CC=2)C=2C=CC=CC=2)=C1 IWEKKSIVEGWURB-UHFFFAOYSA-N 0.000 description 1
- UIYLVOWBKPDQKK-UHFFFAOYSA-N n-(3-nitrophenyl)-3-phenylpyrido[2,3-b]pyrazin-6-amine Chemical compound [O-][N+](=O)C1=CC=CC(NC=2N=C3N=C(C=NC3=CC=2)C=2C=CC=CC=2)=C1 UIYLVOWBKPDQKK-UHFFFAOYSA-N 0.000 description 1
- IZBYBJHSEMDVQG-UHFFFAOYSA-N n-(4-nitrophenyl)-3-phenylpyrido[2,3-b]pyrazin-6-amine Chemical compound C1=CC([N+](=O)[O-])=CC=C1NC1=CC=C(N=CC(=N2)C=3C=CC=CC=3)C2=N1 IZBYBJHSEMDVQG-UHFFFAOYSA-N 0.000 description 1
- LGQYWDNRDRDATQ-UHFFFAOYSA-N n-[(2-chlorophenyl)methyl]-3-phenylpyrido[2,3-b]pyrazin-6-amine Chemical compound ClC1=CC=CC=C1CNC1=CC=C(N=CC(=N2)C=3C=CC=CC=3)C2=N1 LGQYWDNRDRDATQ-UHFFFAOYSA-N 0.000 description 1
- PBWXBAONPRJQDH-UHFFFAOYSA-N n-[(2-fluorophenyl)methyl]-3-phenylpyrido[2,3-b]pyrazin-6-amine Chemical compound FC1=CC=CC=C1CNC1=CC=C(N=CC(=N2)C=3C=CC=CC=3)C2=N1 PBWXBAONPRJQDH-UHFFFAOYSA-N 0.000 description 1
- FGUKQBWHFFTIHE-UHFFFAOYSA-N n-[(2-methylphenyl)methyl]-3-phenylpyrido[2,3-b]pyrazin-6-amine Chemical compound CC1=CC=CC=C1CNC1=CC=C(N=CC(=N2)C=3C=CC=CC=3)C2=N1 FGUKQBWHFFTIHE-UHFFFAOYSA-N 0.000 description 1
- SQSVYMAGEGAQBU-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-3-phenylpyrido[2,3-b]pyrazin-6-amine Chemical compound ClC1=CC=CC(CNC=2N=C3N=C(C=NC3=CC=2)C=2C=CC=CC=2)=C1 SQSVYMAGEGAQBU-UHFFFAOYSA-N 0.000 description 1
- UOPKNFPUMBFMLE-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-3-phenylpyrido[2,3-b]pyrazin-6-amine Chemical compound FC1=CC=CC(CNC=2N=C3N=C(C=NC3=CC=2)C=2C=CC=CC=2)=C1 UOPKNFPUMBFMLE-UHFFFAOYSA-N 0.000 description 1
- GKZDUOIVKONWFF-UHFFFAOYSA-N n-[(3-methylphenyl)methyl]-3-phenylpyrido[2,3-b]pyrazin-6-amine Chemical compound CC1=CC=CC(CNC=2N=C3N=C(C=NC3=CC=2)C=2C=CC=CC=2)=C1 GKZDUOIVKONWFF-UHFFFAOYSA-N 0.000 description 1
- BTIVJQKWJYXECP-UHFFFAOYSA-N n-[(3-nitrophenyl)methyl]-3-phenylpyrido[2,3-b]pyrazin-6-amine Chemical compound [O-][N+](=O)C1=CC=CC(CNC=2N=C3N=C(C=NC3=CC=2)C=2C=CC=CC=2)=C1 BTIVJQKWJYXECP-UHFFFAOYSA-N 0.000 description 1
- WSWZMECUCSVUIL-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-3-phenylpyrido[2,3-b]pyrazin-6-amine Chemical compound C1=CC(Cl)=CC=C1CNC1=CC=C(N=CC(=N2)C=3C=CC=CC=3)C2=N1 WSWZMECUCSVUIL-UHFFFAOYSA-N 0.000 description 1
- XJZILBNOKIGIRM-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-3-phenylpyrido[2,3-b]pyrazin-6-amine Chemical compound C1=CC(F)=CC=C1CNC1=CC=C(N=CC(=N2)C=3C=CC=CC=3)C2=N1 XJZILBNOKIGIRM-UHFFFAOYSA-N 0.000 description 1
- MMMRNXUJQXIJOK-UHFFFAOYSA-N n-[(4-methylphenyl)methyl]-3-phenylpyrido[2,3-b]pyrazin-6-amine Chemical compound C1=CC(C)=CC=C1CNC1=CC=C(N=CC(=N2)C=3C=CC=CC=3)C2=N1 MMMRNXUJQXIJOK-UHFFFAOYSA-N 0.000 description 1
- KAIJXYAEAYSVIF-UHFFFAOYSA-N n-[(4-nitrophenyl)methyl]-3-phenylpyrido[2,3-b]pyrazin-6-amine Chemical compound C1=CC([N+](=O)[O-])=CC=C1CNC1=CC=C(N=CC(=N2)C=3C=CC=CC=3)C2=N1 KAIJXYAEAYSVIF-UHFFFAOYSA-N 0.000 description 1
- SVEUVITYHIHZQE-UHFFFAOYSA-N n-methylpyridin-2-amine Chemical compound CNC1=CC=CC=N1 SVEUVITYHIHZQE-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- RNVCVTLRINQCPJ-UHFFFAOYSA-N o-toluidine Chemical compound CC1=CC=CC=C1N RNVCVTLRINQCPJ-UHFFFAOYSA-N 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000033667 organ regeneration Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 230000008723 osmotic stress Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- RZXMPPFPUUCRFN-UHFFFAOYSA-N p-toluidine Chemical compound CC1=CC=C(N)C=C1 RZXMPPFPUUCRFN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 238000003566 phosphorylation assay Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical class 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 150000003346 selenoethers Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 125000005504 styryl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 230000000982 vasogenic effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6112397P | 1997-10-06 | 1997-10-06 | |
| PCT/US1998/020910 WO1999017759A2 (en) | 1997-10-06 | 1998-10-05 | Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA71555C2 true UA71555C2 (en) | 2004-12-15 |
Family
ID=22033733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2000052578A UA71555C2 (en) | 1997-10-06 | 1998-05-10 | Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US6180631B1 (cs) |
| EP (1) | EP1028729B1 (cs) |
| JP (1) | JP2001518496A (cs) |
| KR (1) | KR100633270B1 (cs) |
| CN (1) | CN1169527C (cs) |
| AR (1) | AR013542A1 (cs) |
| AT (1) | ATE336250T1 (cs) |
| AU (1) | AU757585B2 (cs) |
| BG (1) | BG64969B1 (cs) |
| BR (1) | BR9814814A (cs) |
| CA (1) | CA2306257C (cs) |
| CY (1) | CY1106223T1 (cs) |
| CZ (1) | CZ298775B6 (cs) |
| DE (1) | DE69835612T2 (cs) |
| DK (1) | DK1028729T3 (cs) |
| ES (1) | ES2268791T3 (cs) |
| HK (1) | HK1031836A1 (cs) |
| HU (1) | HUP0100302A3 (cs) |
| IL (2) | IL135103A0 (cs) |
| MX (1) | MXPA03011007A (cs) |
| NO (1) | NO316598B1 (cs) |
| NZ (1) | NZ503431A (cs) |
| PL (1) | PL192039B1 (cs) |
| PT (1) | PT1028729E (cs) |
| RU (1) | RU2223753C2 (cs) |
| SK (1) | SK4722000A3 (cs) |
| TR (2) | TR200000906T2 (cs) |
| TW (1) | TWI245765B (cs) |
| UA (1) | UA71555C2 (cs) |
| WO (1) | WO1999017759A2 (cs) |
| ZA (1) | ZA988961B (cs) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA71555C2 (en) | 1997-10-06 | 2004-12-15 | Zentaris Gmbh | Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| CA2359244C (en) * | 1999-01-13 | 2013-10-08 | Bayer Corporation | .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
| AU1053501A (en) * | 1999-11-02 | 2001-05-14 | Ajinomoto Co., Inc. | Polyazanaphthalene compound and medicinal use thereof |
| US7371763B2 (en) * | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
| US20080108672A1 (en) * | 2002-01-11 | 2008-05-08 | Bernd Riedl | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors |
| DK1478358T3 (da) | 2002-02-11 | 2013-10-07 | Bayer Healthcare Llc | Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese |
| US20040131504A1 (en) * | 2002-09-17 | 2004-07-08 | Landers James P. | Remote temperature sensing of small volume and related apparatus thereof |
| UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
| PT1626714E (pt) * | 2003-05-20 | 2007-08-24 | Bayer Pharmaceuticals Corp | Diarilureias para doenças mediadas por pdgfr |
| DE102004022383A1 (de) * | 2004-05-06 | 2005-12-01 | Zentaris Gmbh | Neue Pyridopyrazine und deren Verwendung als Modulatoren von Kinasen |
| PT1636228E (pt) | 2003-05-23 | 2009-02-02 | Aeterna Zentaris Gmbh | Novas piridopirazinas e sua utilização como moduladores de cinases |
| DE10323345A1 (de) | 2003-05-23 | 2004-12-16 | Zentaris Gmbh | Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren |
| MXPA05013349A (es) * | 2003-06-13 | 2006-03-09 | Novartis Ag | Derivados de 2-amino-pirimidina como inhibidores de quinasa raf. |
| ES2297490T3 (es) | 2003-07-23 | 2008-05-01 | Bayer Pharmaceuticals Corporation | Omega-carboxiarildifenilurea fluoro sustituida para el tratamiento y prevencion de enfermadades y afecciones. |
| EP1790342A1 (de) | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege |
| KR101400905B1 (ko) | 2005-11-11 | 2014-05-29 | 아에테르나 젠타리스 게엠베하 | 신규한 피리도피라진 및 키나제의 조절제로서의 이의 용도 |
| US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
| WO2010003308A1 (zh) * | 2008-07-10 | 2010-01-14 | 卞化石 | 一氧化氮及其信息传递系统在制备恶性肿瘤靶向治疗药物中的应用 |
| GB0812969D0 (en) | 2008-07-15 | 2008-08-20 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| EP2508184A1 (en) | 2011-04-06 | 2012-10-10 | Æterna Zentaris GmbH | Pyridopyrazine derivatives and their use |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| GB201118656D0 (en) * | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| BR112015016580A2 (pt) | 2013-01-11 | 2017-07-11 | Fujifilm Corp | composto heterocíclico contendo nitrogênio ou sal deste |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| DE102013008118A1 (de) * | 2013-05-11 | 2014-11-13 | Merck Patent Gmbh | Arylchinazoline |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| PL3122358T3 (pl) | 2014-03-26 | 2021-06-14 | Astex Therapeutics Ltd. | Połączenia inhibitorów fgfr i cmet w leczeniu nowotworu |
| RU2715893C2 (ru) | 2014-03-26 | 2020-03-04 | Астекс Терапьютикс Лтд | Комбинации ингибитора fgfr и ингибитора igf1r |
| ES2896400T3 (es) | 2014-08-01 | 2022-02-24 | Nuevolution As | Compuestos activos frente a bromdominios |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| BR112018005637B1 (pt) | 2015-09-23 | 2023-11-28 | Janssen Pharmaceutica Nv | Compostos derivados de quinoxalina, quinolina e quinazolinona,composições farmacêuticas que os compreende, e uso dos referidos compostos |
| HUE057090T2 (hu) | 2015-09-23 | 2022-04-28 | Janssen Pharmaceutica Nv | BI-heteroaril-szubsztituált 1,4-benzodiazepinek és alkalmazásuk rák kezelésében |
| US12012394B2 (en) * | 2018-02-19 | 2024-06-18 | Washington University | Alpha-synuclein ligands |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4001017A (en) * | 1972-12-05 | 1977-01-04 | Ciba-Geigy Ag | Process for the photopolymerization of ethylenically unsaturated compounds |
| US4043819A (en) * | 1974-06-11 | 1977-08-23 | Ciba-Geigy Ag | Photo-polymerizable material for the preparation of stable polymeric images and process for making them by photopolymerization in a matrix |
| US5217999A (en) | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
| DE3804990A1 (de) * | 1988-02-18 | 1989-08-31 | Basf Ag | Herbizid wirksame, heterocyclisch substituierte sulfonamide |
| FR2656606B1 (fr) * | 1989-12-28 | 1993-06-25 | Roussel Uclaf | Utilisation de derives du 9,10-dihydrophenanthrene pour la preparation d'un medicament anti-tumoral, application a titre de medicaments de derives du 9,10-dihydrophenanthrene et produits derives de cette structure. |
| ES2064101T3 (es) | 1990-04-02 | 1995-01-16 | Pfizer | Compuestos de acido bencilfosfonico inhibidores de la quinasa de tirosina. |
| US5302606A (en) | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
| WO1992020642A1 (en) | 1991-05-10 | 1992-11-26 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
| JPH06503095A (ja) | 1991-05-29 | 1994-04-07 | ファイザー・インコーポレーテッド | 三環式ポリヒドロキシ系のチロシンキナーゼ阻害薬 |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| AU672224B2 (en) | 1992-08-06 | 1996-09-26 | Warner-Lambert Company | 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and whichhave antitumor properties |
| US5330992A (en) | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
| GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
| US5700823A (en) * | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| GB9501567D0 (en) | 1995-01-26 | 1995-03-15 | Pharmacia Spa | Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors |
| US5593997A (en) * | 1995-05-23 | 1997-01-14 | Pfizer Inc. | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| US5723462A (en) * | 1996-04-26 | 1998-03-03 | Neurogen Corporation | Certain fused pyrrolecarboxamides a new class of GABA brain receptor ligands |
| UA71555C2 (en) | 1997-10-06 | 2004-12-15 | Zentaris Gmbh | Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives |
| GB9726851D0 (en) * | 1997-12-19 | 1998-02-18 | Zeneca Ltd | Human signal transduction serine/threonine kinase |
-
1998
- 1998-05-10 UA UA2000052578A patent/UA71555C2/uk unknown
- 1998-10-01 ZA ZA9808961A patent/ZA988961B/xx unknown
- 1998-10-05 KR KR1020007003656A patent/KR100633270B1/ko not_active IP Right Cessation
- 1998-10-05 WO PCT/US1998/020910 patent/WO1999017759A2/en active IP Right Grant
- 1998-10-05 IL IL13510398A patent/IL135103A0/xx not_active IP Right Cessation
- 1998-10-05 SK SK472-2000A patent/SK4722000A3/sk unknown
- 1998-10-05 BR BR9814814-1A patent/BR9814814A/pt not_active Application Discontinuation
- 1998-10-05 TR TR2000/00906T patent/TR200000906T2/xx unknown
- 1998-10-05 ES ES98948606T patent/ES2268791T3/es not_active Expired - Lifetime
- 1998-10-05 MX MXPA03011007A patent/MXPA03011007A/es not_active IP Right Cessation
- 1998-10-05 US US09/166,723 patent/US6180631B1/en not_active Expired - Fee Related
- 1998-10-05 DE DE69835612T patent/DE69835612T2/de not_active Expired - Fee Related
- 1998-10-05 NZ NZ503431A patent/NZ503431A/en unknown
- 1998-10-05 EP EP98948606A patent/EP1028729B1/en not_active Expired - Lifetime
- 1998-10-05 JP JP2000514630A patent/JP2001518496A/ja not_active Withdrawn
- 1998-10-05 CA CA002306257A patent/CA2306257C/en not_active Expired - Fee Related
- 1998-10-05 TR TR2001/00385T patent/TR200100385T2/xx unknown
- 1998-10-05 AT AT98948606T patent/ATE336250T1/de not_active IP Right Cessation
- 1998-10-05 HU HU0100302A patent/HUP0100302A3/hu not_active Application Discontinuation
- 1998-10-05 CN CNB988099403A patent/CN1169527C/zh not_active Expired - Fee Related
- 1998-10-05 RU RU2000111434/15A patent/RU2223753C2/ru not_active IP Right Cessation
- 1998-10-05 PT PT98948606T patent/PT1028729E/pt unknown
- 1998-10-05 DK DK98948606T patent/DK1028729T3/da active
- 1998-10-05 PL PL339860A patent/PL192039B1/pl not_active IP Right Cessation
- 1998-10-05 AU AU95141/98A patent/AU757585B2/en not_active Ceased
- 1998-10-05 CZ CZ20001129A patent/CZ298775B6/cs not_active IP Right Cessation
- 1998-10-06 AR ARP980104970A patent/AR013542A1/es unknown
- 1998-10-06 TW TW087116559A patent/TWI245765B/zh not_active IP Right Cessation
-
2000
- 2000-03-15 IL IL135103A patent/IL135103A/en unknown
- 2000-04-05 NO NO20001748A patent/NO316598B1/no unknown
- 2000-04-28 BG BG104392A patent/BG64969B1/bg unknown
- 2000-10-16 US US09/688,199 patent/US6727252B1/en not_active Expired - Fee Related
-
2001
- 2001-04-10 HK HK01102529A patent/HK1031836A1/xx not_active IP Right Cessation
-
2006
- 2006-10-30 CY CY20061101554T patent/CY1106223T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA71555C2 (en) | Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives | |
| KR100547929B1 (ko) | 세린/트레오닌 단백질 키나제 기능을 조절하기 위한 아자벤즈이미다졸계 화합물, 이의 제조방법 및 이를 포함하는 약제학적 조성물 | |
| US6204267B1 (en) | Methods of modulating serine/thereonine protein kinase function with quinazoline-based compounds | |
| MXPA00003255A (en) | Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds | |
| MXPA00002910A (en) | Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function | |
| CZ2000990A3 (cs) | Způsob in vitro modulace funkce serin/threonin protein kinázy, způsob in vitro identifikace sloučenin pro tuto modulaci, sloučeniny na bázi azabenzimidazolu,jejich použití, způsob jejich výroby a farmaceutické kompozice |